Recent Investment Analysts’ Ratings Updates for NRx Pharmaceuticals (NRXP)

A number of research firms have changed their ratings and price targets for NRx Pharmaceuticals (NASDAQ: NRXP):

• 1/5/2026 – NRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
• 1/2/2026 – NRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at Ascendiant Capital Markets. They now have a $48.00 price target on the stock, up previously from $47.00.
• 12/29/2025 – NRx Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/23/2025 – NRx Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/17/2025 – NRx Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/16/2025 – NRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 12/3/2025 – NRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.
• 12/2/2025 – NRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
• 11/23/2025 – NRx Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/17/2025 – NRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
• 11/15/2025 – NRx Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/10/2025 – NRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.